Compare Stocks

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Calian Group Ltd. provides business services and solutions in Canada and internationally. It operates through four segment: Advanced Technologies, Health, Learning, and IT and Cyber Solutions (ITCS). The company offers systems engineering, software development, integration design, embedded design, operational management and lifecycle support, modelling and simulation-enabled design, and research & development solutions and services; environmental and radiation protection, decommissioning and waste management, regulatory affairs and licensing, and emergency preparedness and training services; and sophisticated communication systems for the satellite industry, such as antennas, RF systems, decimator RF spectrum analyzers, in-orbit test systems, software defined solutions, operations and teleport services, transmitters, receivers, and modems. It also provides circuit card assemblies, wiring harnesses and cables, units, subsystems and systems, design evolution and qualification testing services, and life cycle management services; DOCSIS network equipment and test solutions; Bin-Sense, an asset monitoring solutions; Fuel Lock for fuel tanks; and composites-specific engineering, metrology and project planning services. In addition, the company offers IT and cyber solution; clinician, nursing, psychological, health property management, patient support program, clinical research, pharmacovigilance, and functional service provider services; and digital health solutions. Further, it provides training for the military, emergency preparedness, and simulation training services; defence manufacturing and engineering, communications and connectivity, and cyber services; military training and simulation services; and health services for military personnel. The company was formerly known as Calian Technologies Ltd. and changed its name to Calian Group Ltd. in April 2016. The company was incorporated in 1982 and is headquartered in Ottawa, Canada.

The SPDR S&P Dividend ETF seeks to closely match the returns and characteristics of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of the 60 highest dividend yielding S&P Composite 1500 Index constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 consecutive years. The Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by the Adviser). SSgA Funds Management, Inc. is the investment adviser to the Fund.